{"id":"orfadin","rwe":[],"tags":[],"safety":{"commonSideEffects":[{"effect":"Elevated tyrosine levels","drugRate":"10%","severity":"common","organSystem":""},{"effect":"Leukopenia","drugRate":"3%","severity":"common","organSystem":""},{"effect":"Thrombocytopenia","drugRate":"3%","severity":"common","organSystem":""},{"effect":"Conjunctivitis","drugRate":"2%","severity":"common","organSystem":""},{"effect":"Corneal opacity","drugRate":"2%","severity":"common","organSystem":""},{"effect":"Keratitis","drugRate":"2%","severity":"common","organSystem":""},{"effect":"Photophobia","drugRate":"2%","severity":"common","organSystem":""},{"effect":"Eye pain","drugRate":"1%","severity":"common","organSystem":""},{"effect":"Blepharitis","drugRate":"1%","severity":"common","organSystem":""},{"effect":"Cataracts","drugRate":"1%","severity":"common","organSystem":""},{"effect":"Granulocytopenia","drugRate":"1%","severity":"common","organSystem":""},{"effect":"Epistaxis","drugRate":"1%","severity":"common","organSystem":""},{"effect":"Pruritus","drugRate":"1%","severity":"common","organSystem":""},{"effect":"Exfoliative dermatitis","drugRate":"1%","severity":"common","organSystem":""},{"effect":"Dry skin","drugRate":"1%","severity":"common","organSystem":""},{"effect":"Maculopapular rash","drugRate":"1%","severity":"common","organSystem":""},{"effect":"Alopecia","drugRate":"1%","severity":"common","organSystem":""}],"contraindications":["Hypertyrosinemia","Hypophosphatemia","Kidney disease","Leukopenia","Pain in eye","Photophobia","Red eye","Thrombocytopenic disorder"],"seriousAdverseEvents":[{"effect":"Liver transplantation","drugRate":"13%","severity":"serious"},{"effect":"Liver failure","drugRate":"7%","severity":"serious"},{"effect":"Malignant hepatic neoplasms","drugRate":"5%","severity":"serious"},{"effect":"Benign hepatic neoplasms","drugRate":"3%","severity":"serious"},{"effect":"Porphyria","drugRate":"1%","severity":"serious"},{"effect":"Death","drugRate":"<1.0%","severity":"serious"},{"effect":"Seizure","drugRate":"<1.0%","severity":"serious"},{"effect":"Brain tumor","drugRate":"<1.0%","severity":"serious"},{"effect":"Encephalopathy","drugRate":"<1.0%","severity":"serious"},{"effect":"Gastrointestinal hemorrhage","drugRate":"<1.0%","severity":"serious"}]},"trials":[],"_chembl":{"chemblId":"CHEMBL1337","moleculeType":"Small molecule","molecularWeight":"329.23"},"aliases":["Nitisinone"],"patents":[],"pricing":[],"_fixedAt":"2026-03-30T18:29:57.380344","_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Orfadin","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:38:42.589041+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:38:49.151498+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Orfadin","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:38:49.832544+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: 4-hydroxyphenylpyruvate dioxygenase inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:38:50.381971+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1337/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:38:50.289403+00:00"}},"offLabel":[],"timeline":[],"_dailymed":{"setId":"00307f42-748d-4227-8c6f-ed5f0a89ae0a","title":"ORFADIN (NITISINONE) SUSPENSION [SWEDISH ORPHAN BIOVITRUM AB (PUBL)]"},"ecosystem":[],"mechanism":{"target":"4-hydroxyphenylpyruvate dioxygenase, 4-hydroxyphenylpyruvate dioxygenase","modality":"Small Molecule"},"_scrapedAt":"2026-03-28T04:19:23.205Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:38:52.406173+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Homogentisate 1,2dioxygenase deficiency","diseaseId":"homogentisate-12dioxygenase-deficiency","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Tyrosinemia type I","diseaseId":"tyrosinemia-type-i","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"_fixedFields":["sideEffects","modality→Small Molecule"],"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06227429","phase":"","title":"A Non-interventional, Post-Marketing Study to Describe Outcome of Nitisinone Treatment in HT-1 Patients","status":"WITHDRAWN","sponsor":"Swedish Orphan Biovitrum","startDate":"2025-09","conditions":"Hereditary Tyrosinemia, Type I","enrollment":""},{"nctId":"NCT02320084","phase":"","title":"Long Term Safety Study of Orfadin Treatment in HT-1 Patients in Standard Clinical Care","status":"COMPLETED","sponsor":"Swedish Orphan Biovitrum","startDate":"2013-09","conditions":"Hereditary Tyrosinemia, Type I","enrollment":315},{"nctId":"NCT01857362","phase":"PHASE1","title":"Bioequivalence of Orfadin 20 mg Compared to Orfadin 10 mg Capsules.","status":"COMPLETED","sponsor":"Swedish Orphan Biovitrum","startDate":"2013-05","conditions":"Healthy","enrollment":12},{"nctId":"NCT00107783","phase":"PHASE2","title":"Long-Term Study of Nitisinone to Treat Alkaptonuria","status":"COMPLETED","sponsor":"National Human Genome Research Institute (NHGRI)","startDate":"2005-01","conditions":"Alkaptonuria","enrollment":40},{"nctId":"NCT01390077","phase":"PHASE2, PHASE3","title":"Nitisinone (NTBC) In Different Age Groups Of Patients With Alkaptonuria","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2011-01","conditions":"Alkaptonuria","enrollment":8},{"nctId":"NCT04113772","phase":"NA","title":"Bio Equivalency 20 Mgm Orfadin and 20 Mgm of Nitisonine","status":"UNKNOWN","sponsor":"Sutphin Drugs","startDate":"2019-11-01","conditions":"Hereditary Tyrosinemia, Type I","enrollment":4},{"nctId":"NCT01838655","phase":"PHASE1, PHASE2","title":"Nitisinone for Type 1B Oculocutaneous Albinism","status":"COMPLETED","sponsor":"National Eye Institute (NEI)","startDate":"2013-04-16","conditions":"Albinism, Vision Loss","enrollment":5},{"nctId":"NCT01916382","phase":"PHASE3","title":"Suitability of Nitisinone in Alkaptonuria 2","status":"UNKNOWN","sponsor":"University of Liverpool","startDate":"2014-04","conditions":"Alkaptonuria","enrollment":140},{"nctId":"NCT03103568","phase":"PHASE1","title":"A Study to Investigate the Potential Influence of Nitisinone on the Metabolism and the Transport of Other Drugs in Healthy Volunteers","status":"COMPLETED","sponsor":"Swedish Orphan Biovitrum","startDate":"2017-03-28","conditions":"Drug Drug Interaction","enrollment":36},{"nctId":"NCT02750345","phase":"PHASE1","title":"Bioequivalence Study of Two Oral Nitisinone Formulations to Treat Hereditary Tyrosinemia (HT-1)","status":"COMPLETED","sponsor":"Cycle Pharmaceuticals Ltd.","startDate":"2016-03","conditions":"Hereditary Tyrosinemia, Type I","enrollment":24},{"nctId":"NCT02750332","phase":"PHASE1","title":"Bioavailability Food-Effect Study of an Oral Nitisinone Formulation to Treat Hereditary Tyrosinemia (HT-1)","status":"COMPLETED","sponsor":"Cycle Pharmaceuticals Ltd.","startDate":"2015-11","conditions":"Hereditary Tyrosinemia, Type I","enrollment":20},{"nctId":"NCT02750709","phase":"PHASE1","title":"Bioequivalence Study of Two Nitisinone Formulations Compared to Orfadin","status":"COMPLETED","sponsor":"Cycle Pharmaceuticals Ltd.","startDate":"2015-10","conditions":"Hereditary Tyrosinemia, Type I","enrollment":24},{"nctId":"NCT02323529","phase":"PHASE3","title":"Efficacy and Safety of Once Daily Dosing Compared to Twice Daily Dosing of Nitisinone in HT-1","status":"COMPLETED","sponsor":"Swedish Orphan Biovitrum","startDate":"2014-12","conditions":"Hereditary Tyrosinemia, Type I","enrollment":18},{"nctId":"NCT00031161","phase":"NA","title":"Prevention of Dichloroacetate Toxicity","status":"COMPLETED","sponsor":"University of Florida","startDate":"2001-09","conditions":"Acidosis, Lactic, Chronic Disease","enrollment":30},{"nctId":"NCT01734889","phase":"PHASE1","title":"Taste and Palatability of Orfadin Suspension","status":"COMPLETED","sponsor":"Swedish Orphan Biovitrum","startDate":"2012-10","conditions":"Hereditary Tyrosinemia, Type I","enrollment":18},{"nctId":"NCT01828463","phase":"PHASE2","title":"Dose Response Study of Nitisinone in Alkaptonuria","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2013-05","conditions":"Alkaptonuria","enrollment":40},{"nctId":"NCT01682538","phase":"PHASE1","title":"Bioequivalence of Orfadin Suspension Compared to Orfadin Capsules, and the Effect of Food on the Bioavailability of the Suspension","status":"COMPLETED","sponsor":"Swedish Orphan Biovitrum","startDate":"2012-08","conditions":"Healthy Volunteers","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"chemblId":"CHEMBL1337"},"formularyStatus":[],"_approvalHistory":[{"date":"20170901","type":"SUPPL","sponsor":"SWEDISH ORPHAN","applicationNumber":"NDA206356"},{"date":"20160422","type":"ORIG","sponsor":"SWEDISH ORPHAN","applicationNumber":"NDA206356"},{"date":"20190517","type":"SUPPL","sponsor":"SWEDISH ORPHAN","applicationNumber":"NDA206356"},{"date":"20170616","type":"SUPPL","sponsor":"SWEDISH ORPHAN","applicationNumber":"NDA206356"},{"date":"20160830","type":"SUPPL","sponsor":"SWEDISH ORPHAN","applicationNumber":"NDA206356"},{"date":"20020118","type":"ORIG","sponsor":"SWEDISH ORPHAN","applicationNumber":"NDA021232"},{"date":"20150605","type":"SUPPL","sponsor":"SWEDISH ORPHAN","applicationNumber":"NDA021232"},{"date":"20141030","type":"SUPPL","sponsor":"SWEDISH ORPHAN","applicationNumber":"NDA021232"},{"date":"20170901","type":"SUPPL","sponsor":"SWEDISH ORPHAN","applicationNumber":"NDA021232"},{"date":"20130621","type":"SUPPL","sponsor":"SWEDISH ORPHAN","applicationNumber":"NDA021232"},{"date":"20130213","type":"SUPPL","sponsor":"SWEDISH ORPHAN","applicationNumber":"NDA021232"},{"date":"20170228","type":"SUPPL","sponsor":"SWEDISH ORPHAN","applicationNumber":"NDA021232"},{"date":"20160613","type":"SUPPL","sponsor":"SWEDISH ORPHAN","applicationNumber":"NDA021232"},{"date":"20190517","type":"SUPPL","sponsor":"SWEDISH ORPHAN","applicationNumber":"NDA021232"},{"date":"20141027","type":"SUPPL","sponsor":"SWEDISH ORPHAN","applicationNumber":"NDA021232"},{"date":"20140521","type":"SUPPL","sponsor":"SWEDISH ORPHAN","applicationNumber":"NDA021232"},{"date":"20100125","type":"SUPPL","sponsor":"SWEDISH ORPHAN","applicationNumber":"NDA021232"},{"date":"20130402","type":"SUPPL","sponsor":"SWEDISH ORPHAN","applicationNumber":"NDA021232"}],"developmentCodes":[],"ownershipHistory":[],"publicationCount":18,"therapeuticAreas":["Other"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Orfadin","genericName":"Orfadin","companyName":"Cycle Pharmaceuticals Ltd.","companyId":"cycle-pharmaceuticals-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:38:52.406173+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}